```html

Zollinger‑Ellison Disease (Type I) – Comprehensive Medical Guide

Overview

Zollinger‑Ellison disease (ZED) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach to produce large amounts of acid. The resulting hyperacidic environment causes severe peptic ulcer disease, chronic diarrhea, and malabsorption.

Although the term “Zollinger‑Ellison syndrome” is often used, the modern classification separates type I (the classic sporadic gastrinoma) from type II (associated with multiple endocrine neoplasia type 1, MEN‑1) and type III (aggressive, sporadic tumors). This guide focuses on **type I**, the most common form.

• Incidence: Approximately 0.1–1 case per million people per year.<sup>[1] NIH</sup>
• Gender: Slight male predominance (≈55 % male).<sup>[2] Mayo Clinic</sup>
• Age at diagnosis: Median 45–55 years, but cases range from teens to elderly.

Symptoms

Symptoms result from excess gastric acid and the mass effect of the tumor.

Gastrointestinal Manifestations

• Refractory peptic ulcer disease – ulcers that fail to heal with standard therapy, often multiple and located distal to the duodenum (jejunum, ileum).
• Epigastric or upper abdominal pain – burning or gnawing pain, often worsened by meals.
• Chronic diarrhea – watery, sometimes fatty (steatorrhea) due to acid‑induced damage to the intestinal mucosa.
• Nausea & vomiting – may be related to ulcer complications or gastric outlet obstruction.
• Gastro‑esophageal reflux disease (GERD) – heartburn from the high‑acid load.

Systemic/Other Manifestations

• Weight loss – secondary to malabsorption, diarrhea, and decreased appetite.
• Fatigue – from anemia (occult bleeding) or nutrient deficiencies.
• Bleeding – melena or hematemesis if ulcers erode vessels.
• Signs of malnutrition – low vitamin B12, iron, calcium, or magnesium levels.
• Abdominal mass – occasionally palpable if tumor is large.

Causes and Risk Factors

Type I ZED is usually **sporadic**, meaning it occurs without an inherited syndrome. The exact cause of gastrinoma formation is unknown, but several mechanisms have been proposed.

• Somatic mutations in the MEN1 gene or VHL gene have been identified in a minority of sporadic cases.<sup>[3] Cleveland Clinic</sup>
• Chronic hypergastrinemia (e.g., from long‑term proton‑pump inhibitor use) can theoretically promote entero‑chromaffin‑like cell hyperplasia, though a direct causal link to gastrinomas is unproven.
• Environmental exposures – limited data; no clear occupational or dietary risk has been established.

Risk groups (though most cases are truly idiopathic):

• Adults aged 40–60 years.
• Male sex (slight excess).
• Individuals with a personal or family history of other neuroendocrine tumors.
• Patients with MEN‑1 (type II), which is *not* type I but important for differential diagnosis.

Diagnosis

Because ZED mimics common ulcer disease, a high index of suspicion is essential—especially when ulcers are refractory, atypical, or recurrent.

Clinical Evaluation

• Detailed history (ulcer recurrence, diarrhea, weight loss).
• Physical exam (abdominal tenderness, signs of anemia or malnutrition).

Laboratory Tests

• Fasting serum gastrin level – > 1000 pg/mL (or > 10× upper limit) strongly suggests gastrinoma, especially after a secretin stimulation test.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is diagnostic.
• Electrolytes, calcium, magnesium, iron studies, and vitamin B12 to assess malabsorption.
• CBC to detect anemia from occult bleeding.

Imaging Studies

• Somatostatin receptor scintigraphy (SRS) / ^68Ga‑DOTATATE PET‑CT – most sensitive for locating gastrinomas.
• CT or MRI of the abdomen – helps define tumor size, location, and metastatic spread.
• EUS (endoscopic ultrasound) – excellent for detecting small (< 1 cm) pancreatic lesions.
• Upper endoscopy (EGD) – visualizes ulcers and can obtain biopsies to rule out malignancy.

Pathology

If surgery is performed, histology confirms a neuroendocrine tumor with positive chromogranin A and synaptophysin staining, plus elevated gastrin immunoreactivity.

Treatment Options

Management combines **acid suppression**, **tumor control**, and **nutritional support**.

Medical Therapy

• Proton‑pump inhibitors (PPIs) – high‑dose, long‑acting agents (e.g., omeprazole 60 mg daily or equivalent) are first‑line to neutralize acid and heal ulcers. Doses may be titrated upward until symptoms resolve and gastrin levels normalize.<sup>[4] Mayo Clinic</sup>
• H2‑receptor antagonists – adjunctive if PPIs are insufficient.
• Octreotide or lanreotide (somatostatin analogues) – reduce gastrin secretion and can shrink tumor size, especially in metastatic disease.
• Chemotherapy & targeted therapy – reserved for aggressive, metastatic gastrinomas. Agents such as everolimus or sunitinib have shown benefit in neuroendocrine tumors.

Surgical Options

• Enucleation – removal of a solitary, well‑located gastrinoma; preferred when no metastasis.
• Pancreatic resection (e.g., distal pancreatectomy) – for larger or multiple pancreatic lesions.
• Duodenal wedge resection – for gastrinomas in the duodenum.
• Debulking surgery – may improve symptom control when complete resection is impossible.

Liver‑Directed Therapies (for metastatic disease)

• Radiofrequency ablation, hepatic arterial embolization, or peptide receptor radionuclide therapy (PRRT).

Lifestyle & Supportive Care

• Small, frequent meals to limit gastric acid spikes.
• Avoidance of NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
• Supplementation with calcium, vitamin D, and iron as needed.
• Regular monitoring of gastrin levels and imaging every 6–12 months.

Living with Zollinger‑Ellison Disease (Type I)

Effective long‑term control hinges on adherence to medication, nutrition, and follow‑up.

• Medication adherence – never miss a PPI dose; carry a rescue dose for breakthrough symptoms.
• Routine labs – check gastrin, electrolytes, and nutritional markers every 3–6 months.
• Dietary tips –
  • Low‑fat, low‑spice diet; avoid citrus, tomato products, chocolate, and caffeine if they trigger symptoms.
  • Include probiotic‑rich foods (yogurt, kefir) to support gut health.
• Physical activity – moderate exercise improves gastrointestinal motility and overall well‑being.
• Psychosocial support – chronic disease can cause anxiety; counseling or support groups (e.g., Neuroendocrine Tumor Patient Foundation) are valuable.
• Vaccinations – keep hepatitis B and pneumococcal vaccines up to date, especially if undergoing systemic therapy.

Prevention

Because type I ZED is largely sporadic, primary prevention is limited. However, certain measures can lower the chance of complications and may theoretically reduce risk:

• Use NSAIDs and aspirin only when medically indicated and with gastro‑protective agents.
• Limit long‑term, high‑dose PPI use unless prescribed for proven conditions; unnecessary acid suppression may alter gastric hormone feedback.
• Maintain a healthy weight and avoid smoking, which are general risk‑reduction strategies for pancreatic neoplasms.

Complications

If untreated or inadequately controlled, ZED can lead to serious health problems.

• Perforated ulcer – emergency surgery required.
• Gastrointestinal bleeding – can cause anemia and hemodynamic instability.
• Strictures or gastric outlet obstruction – may need dilation or surgery.
• Malabsorption & osteoporosis – chronic acid damage impairs calcium and vitamin D absorption.
• Metastatic gastrinoma – liver is most common site; reduces survival if not managed.
• Neuroendocrine tumor syndrome – rare, but multiple endocrine organs can be involved, especially if a MEN‑1 mutation is later discovered.

When to Seek Emergency Care

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” Updated 2023. NIH
2. Mayo Clinic. “Zollinger‑Ellison syndrome.” 2022. Mayo Clinic
3. Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” 2023. Cleveland Clinic
4. World Gastroenterology Organisation Global Guidelines. “Peptic ulcer disease.” 2021.
5. American Cancer Society. “Neuroendocrine Tumors of the Pancreas.” 2024. ACS

```